The Prognostic Value of
Colorectal cancer
KRAS mutation
18F-fluoro-deoxy-glucose positron emission tomography/computerized tomography (18F-FDG PET/CT)
prognosis
Journal
Molecular imaging and radionuclide therapy
ISSN: 2146-1414
Titre abrégé: Mol Imaging Radionucl Ther
Pays: Turkey
ID NLM: 101584839
Informations de publication
Date de publication:
17 Feb 2020
17 Feb 2020
Historique:
entrez:
22
2
2020
pubmed:
23
2
2020
medline:
23
2
2020
Statut:
ppublish
Résumé
Prognostic effect of KRAS mutation and side of tumor in colorectal cancer is a highly controversial subject. Therefore, we evaluated the association between FDG uptake pattern in Eighty-three patients with colorectal cancer were retrospectively included in this study. Twenty five patients were female while 58 were male. The mean age of the patients was 59.8±11.3 years. Mean follow-up was 35.5±18.9 months. Primary tumor was localized in the left colon in 83.1% of patients and in the right colon in 16.9%. KRAS mutation was detected in 54.2% (n=45) of patients. Mean SUV In our study, we found that tumor localization had no significant effect on prognosis in patients with colon cancer. On the other hand, FDG uptake was observed to be higher in the presence of KRAS mutation and it was concluded that coexistence of KRAS mutation with higher SUV Kolorektal kanserde KRAS mutasyonu ve tümörün lokalizasyonu ile ilişkili prognostik etki tartışmalı bir konudur. Bu nedenle Kolorektal kanser tanılı 83 hasta retrospektif olarak bu çalışmaya dahil edildi. Tedavi öncesi evreleme için Olguların 25’i kadın, 58’i erkekti. Hastaların yaş ortalaması 59,8±11,3 idi. Ortalama takip süresi 35,5±18,9 aydı. Primer tümör hastaların %83,1’inde sol kolonda ve %16,9’unda sağ kolonda lokalize idi. KRAS mutasyonu hastaların %54,2’sinde (n=45) tespit edildi. Primer tümörün ortalama SUV Çalışmamızda, kolon tümörü lokalizasyonunun prognoz üzerinde anlamlı bir etkisinin olmadığını bulduk. Öte yandan, FDG tutulumunun KRAS mutasyonu varlığında daha yüksek olduğu gözlendi ve KRAS mutasyonunun yüksek SUV
Autres résumés
Type: Publisher
(tur)
Kolorektal kanserde KRAS mutasyonu ve tümörün lokalizasyonu ile ilişkili prognostik etki tartışmalı bir konudur. Bu nedenle
Identifiants
pubmed: 32079384
doi: 10.4274/mirt.galenos.2019.33866
pmc: PMC7057728
doi:
Types de publication
Journal Article
Langues
eng
Pagination
17-24Références
Surg Oncol Clin N Am. 2018 Apr;27(2):243-267
pubmed: 29496088
Arch Pathol Lab Med. 2010 Jun;134(6):837-52
pubmed: 20524862
Mol Med. 2016 May;21(1):1038-1046
pubmed: 26716438
PLoS One. 2015 May 29;10(5):e0126891
pubmed: 26024321
JAMA Oncol. 2017 Oct 1;3(10):1386-1392
pubmed: 28594974
Cancer Biomark. 2016 Mar 4;16(4):513-21
pubmed: 27062566
J Clin Oncol. 2010 Jan 20;28(3):466-74
pubmed: 20008640
Breast Cancer Res Treat. 2015 Feb;150(1):209-17
pubmed: 25697596
J Nucl Med. 2009 Jan;50(1):88-99
pubmed: 19139187
JAMA Surg. 2013 Aug;148(8):747-54
pubmed: 23784448
Clin Cancer Res. 2009 Dec 1;15(23):7322-9
pubmed: 19934290
J Oncol. 2019 Feb 21;2019:4315032
pubmed: 30915121
J Mol Cell Biol. 2019 Apr 1;11(4):267-276
pubmed: 30496442
BMC Cancer. 2017 Apr 17;17(1):275
pubmed: 28415990
Am J Nucl Med Mol Imaging. 2014 Aug 15;4(5):471-82
pubmed: 25143865
J Nucl Med. 2014 Jun;55(6):891-7
pubmed: 24752672
Ann Surg Oncol. 2015 Jan;22(1):187-94
pubmed: 24889488
J Nucl Med. 2016 Feb;57 Suppl 1:17S-26S
pubmed: 26834096
Nat Genet. 2008 May;40(5):600-8
pubmed: 18372904
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
JAMA Oncol. 2017 Feb 1;3(2):211-219
pubmed: 27787550